AS­CO spot­light pre­saged two more biotech IPOs an­gling for $215M

Two biotechs which spot­light­ed new can­cer da­ta dur­ing the last round at AS­CO in ear­ly June are lin­ing up IPOs to help fund their late-stage R&D work. Both com­pa­nies filed in the lead-up to the long week­end.

First up is the on­col­o­gy-fo­cused De­ci­phera, which filed for a $100 mil­lion IPO just three months af­ter bank­ing a $52 mil­lion crossover round.

Some­where along the way, De­ci­phera ap­pears to have dropped its ini­tial lead ther­a­py — al­ti­ra­tinib — for rea­sons un­known to me. In its place, the biotech has been push­ing along an ear­ly-stage pro­gram for DCC-2618 along with an even ear­li­er-stage work on the im­muno-on­col­o­gy as­set DCC-3014. Re­bas­tinib is its third clin­i­cal-stage as­set.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER